GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660)

Q4 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript

May 13, 2025 / 10:59 AM GMT

Release Date Price: ₹2790.15 (+2.53%)

Transcript

Key Points

Positve

GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) reported a 9% revenue growth, predominantly led by volume growth.
The company achieved a 30% growth in EBITDA, with margins improving from 26% to 31% year-over-year.
Significant progress in digital strategy, with over 400,000 unique SCP touchpoints through omnichannel and digital strategies.
Strong performance in the specialty segment with a 35% growth, and stable growth in vaccines at 12%.
The company has a healthy balance sheet with zero debt and a cash reserve of approximately 2,500 crore.

Negative

The external landscape did not evolve as expected, particularly affecting the acute segments of the Indian pharmaceutical market.
The company faces challenges with more than half of its portfolio under price control, limiting pricing flexibility.
There is a significant difference between reported primary sales and secondary sales numbers, particularly in non-promoted portfolios and vaccines.
The antibiotics segment experienced a soft quarter, impacting overall revenue growth.
The company is cautious about further margin expansion, indicating stabilization at current levels.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GLAX.NS - GlaxoSmithKline Pharmaceuticals Ltd
Q4 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call
May 13, 2025 / NTS GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hi, good evening, everyone. This is Zico Pereira, your moderator from Chorus Call.

Welcome to the GlaxoSmithli Pharmaceuticals Limited, Q4 FY 2025 and full year earnings call.

From the management at GlaxoSmithline Pharmaceuticals Limited, we have Mr. Bushan Nashika, managing director Glaxo Smith Kline Pharmaceuticals Limited, and Mr. Jovi Chandy, Chief Financial Officer, Glaxo Smith Kline Pharmaceuticals Limited.

By participating in this event you consent to the recording, distribution and publication of this event.

Kindly note that this call is meant for investors and analysts only.

All participant lines will be in the listen-only mode. There will be an

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.